VEGZELMA (bevacizumab-adcd) · CELLTRION INC
VEGZELMA is a vascular endothelial growth factor inhibitor indicated for the treatment of several types of metastatic, recurrent, or advanced malignancies. It is used in the management of colorectal, non-squamous non-small cell lung, renal cell, and cervical cancers, as well as glioblastoma and certain gynecological cancers. Depending on the specific indication, the drug is administered as a first-line or subsequent therapy, often in combination with various chemotherapy regimens. Its therapeutic role focuses on inhibiting tumor-related vascular growth in patients with advanced disease.
How VEGZELMA Works
VEGZELMA works by binding to vascular endothelial growth factor (VEGF), preventing it from interacting with its receptors on the surface of endothelial cells. Under normal conditions, the interaction between VEGF and its receptors stimulates the proliferation of these cells and the formation of new blood vessels. By blocking this pathway, the drug inhibits the process of angiogenesis, which reduces microvascular growth. This mechanism serves to limit the progression of metastatic disease by restricting the blood supply required for tumor growth.
Details
- Status
- Prescription
- First Approved
- 2022-09-27
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
VEGZELMA Approval History
What VEGZELMA Treats
8 indicationsVEGZELMA is approved for 8 conditions since its original approval in 2022. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Metastatic Colorectal Cancer
- Non-Small Cell Lung Cancer
- Glioblastoma
- Metastatic Renal Cell Carcinoma
- Cervical Cancer
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer
VEGZELMA Target & Pathway
ProTarget
A signaling protein that stimulates the formation of new blood vessels (angiogenesis). Tumors need blood supply to grow, so they secrete VEGF to create new vessels. Blocking VEGF starves tumors of oxygen and nutrients, inhibiting their growth.
Pathway Context
VEGF binds to VEGFR on blood vessel cells to stimulate new vessel formation
Receptors on blood vessel cells that respond to VEGF signals to form new blood vessels. Cancer cells exploit this pathway to ensure blood supply for tumor growth. Blocking VEGFRs prevents tumor angiogenesis and limits cancer progression.
VEGZELMA is a lower-cost alternative to Avastin with no clinically meaningful differences. Requires prescriber approval to substitute.
VEGZELMA Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in VEGZELMA's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications VEGZELMA treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to VEGZELMA
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VEGZELMA FDA Label Details
Indications & Usage
FDA Label (PDF)VEGZELMA is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. Limitations of Use : VEGZELMA is not indicated for adjuvant treatment of colon cancer. Unresectable, locally advanced, recurrent or me...
Track VEGZELMA with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.